5 results
Primary objective:To demonstrate bioequivalence of GP2015 applied by an autoinjector (delta-GP2015_50) and a pre-filled syringe (PFS) as single subcutaneous injection of 50 mg to healthy adult male subjectsSecondary objectives- To study and compare…
The primary objective of the study is to evaluate the safety, tolerability, PK, and PD of AL002 administered in single ascending doses in healthy participants and multiple doses in participants with mild to moderate AD.
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…
The primary objectives of this add-on Phase 2 LTE study (see Table 1) are to evaluate the long-term safety and tolerability of IMP at three possible doses (ie, 15 mg/kg, 40 mg/kg, and 60 mg/kg) and to assess the effect of dose titration on the…
To evaluate the efficacy of AL002 in participants with Early AD in delaying disease progression compared to standard of care